Based on these observations, the authors propose that when Trousseau’s syndrome develops in patients with lung cancer, continuous heparin therapy should be initiated, and genetic testing along with PD-L1 immunostaining should be promptly performed to guide appropriate treatment. This evidence concerns the gene CD274 and lung carcinoma.